House Bill 2817
Sponsored by Representatives TOMEI, GREENLICK; Representatives BARKER, BARNHART, BEYER, BOONE, BUCKLEY, DINGFELDER, GALIZIO, GARRARD, HANSEN, HASS, HOLVEY, HUNT, JENSON, KOMP, NOLAN, RILEY, ROBLAN, ROSENBAUM, SHIELDS, WITT

SUMMARY
The following summary is not prepared by the sponsors of the measure and is not a part of the body thereof subject to consideration by the Legislative Assembly. It is an editor’s brief statement of the essential features of the measure as introduced.

Requires pharmaceutical manufacturing companies to disclose certain economic benefits provided in conjunction with marketing of prescription drugs. Authorizes imposition of civil penalty for failure to disclose required information. Directs Department of Justice to report disclosures to Legislative Assembly and Governor.

Establishes Pharmaceutical Marketing Disclosure Fund. Appropriates moneys in fund to Department of Justice for administration of Act.
Declares emergency, effective on passage.

A BILL FOR AN ACT
Relating to disclosure of economic benefits provided by pharmaceutical manufacturing companies; Appropriating money; and declaring an emergency.

Be It Enacted by the People of the State of Oregon:

SECTION 1. (1) All pharmaceutical manufacturing companies shall disclose annually to the Department of Justice the value, nature and purpose of any gift, fee, payment, subsidy or other economic benefit that is provided to any physician, hospital, nursing home, pharmacist, health benefit plan administrator or other person authorized to prescribe or dispense prescription drugs in this state in connection with detailing, promotional or other marketing activities by the company directly or through a pharmaceutical marketer acting on behalf of the company.

(2) The disclosure required under subsection (1) of this section must:
(a) Be made annually by February 15;
(b) Cover the calendar year ending on December 31 preceding the reporting date;
(c) Include the name and address of the individual responsible for compliance by the company with the requirements of subsection (1) of this section; and
(d) Be made in the manner established by the department by rule.

(3) The Department of Justice shall report annually by April 1 on the disclosures received under this section to the Legislative Assembly in the manner provided in ORS 192.245 and to the Governor.

(4) The Department of Justice shall keep confidential all information reported under subsection (1) of this section that qualifies as a trade secret as that term is described in ORS 192.501.

(5) The following are exempt from disclosure under this section:
(a) Free samples of prescription drugs intended to be distributed to patients;
(b) Payment of reasonable compensation and reimbursement of expenses for bona fide clinical trials;

NOTE: Matter in boldfaced type in an amended section is new; matter [italic and bracketed] is existing law to be omitted. New sections are in boldfaced type.

LC 1380
(c) Any gift, fee, payment, subsidy or economic benefit with a value of less than $25; and
(d) Scholarships or other support for medical students, residents or fellows to attend
educational, scientific or policy-making conferences of a national, regional, medical specialty
or other professional association if the recipients of the scholarships or other support are
selected by the association.

(6) The Department of Justice shall adopt rules necessary for the administration of this
section.

(7) As used in this section:

(a) “Pharmaceutical manufacturing company” means an entity engaged in the produc-
tion, preparation, propagation, compounding, conversion or processing of prescription
drugs, either directly or indirectly by extraction from substances of natural origin or inde-
dependently by means of chemical synthesis, or by a combination of extraction and chemical
synthesis, or an entity engaged in the packaging, repackaging, labeling or distribution of
prescription drugs. “Pharmaceutical manufacturing company” does not include a pharmacist
licensed under ORS chapter 689.

(b) “Pharmaceutical marketer” means a person who, while employed by or under con-
tact to represent a pharmaceutical manufacturing company, engages in detailing, promo-
tional or other marketing activities of prescription drugs in this state to any physician,
hospital, nursing home, pharmacist, health benefit plan administrator or other person au-
thorized to prescribe or dispense prescription drugs in this state.

SECTION 2. (1) The Department of Justice may impose a civil penalty of up to $10,000 for
each violation of section 1 of this 2005 Act. Each gift, fee, payment, subsidy or other eco-
nomic benefit not disclosed as required by section 1 of this 2005 Act constitutes a separate
violation of section 1 of this 2005 Act.

(2) Civil penalties under this section shall be imposed in the manner provided by ORS
183.745.

SECTION 3. The Pharmaceutical Marketing Disclosure Fund is established, separate and
distinct from the General Fund. All moneys received under section 2 of this 2005 Act shall
be credited to the Pharmaceutical Marketing Disclosure Fund and are continuously appro-
priated to the Department of Justice for the purposes of administering section 1 of this 2005
Act.

SECTION 4. This 2005 Act being necessary for the immediate preservation of the public
peace, health and safety, an emergency is declared to exist, and this 2005 Act takes effect
on its passage.